Acquisition adds Phase 2 ready novel VISTA inhibiting monoclonal antibody (mAb) to TuHURA's late-stage immuno-oncology pipeline TuHURA planning to initiate a Phase ...

Acquisition adds Phase 2 ready novel VISTA inhibiting monoclonal antibody (mAb) to TuHURA's late-stage immuno-oncology pipeline TuHURA planning to ...

Felzartamab's mechanism of action designed to deplete the cells that produce ... About Felzartamab Felzartamab is an investigational therapeutic human monoclonal antibody directed against CD38, a ...

Global Phase 3 PROMINENT study will evaluate the efficacy and safety of felzartamab, as compared to tacrolimus, in adults ...

During early drug development and preclinical development, researchers use in vitro cultured lymphocytes to induce cytokine ...

Calico will leverage 9MW3811’s anti-inflammatory mechanism to advance its mission of addressing aging-related diseases.

The anti-CCR8 antibodies market holds potential in addressing unmet needs across inflammatory and cancerous diseases. The anti-CCR8 inhibitor market is ...

Paris: Sanofi has announced that the US Food and Drug Administration (FDA) has granted orphan drug designation to Riliprubart ...

US FDA grants orphan drug designation to Sanofi’s riliprubart for antibody-mediated rejection in solid organ transplantation: Paris Thursday, June 26, 2025, 09:00 Hrs [IST] The ...

Riliprubart earns orphan drug designation in the US for antibody-mediated rejection in solid organ transplantation <li /> Ongoing phase 2 ...

Press Release Distributed by ABNewswire.com To view the original version on ABNewswire visit: Kidney Transplant Rejection ...

Cidara Therapeutics has reported encouraging top-line outcomes from the Phase IIb NAVIGATE trial of the investigational drug-Fc conjugate (DFC), CD388, for seasonal influenza prevention in healthy ...